HomeComparePRTK vs GIS

PRTK vs GIS: Dividend Comparison 2026

PRTK yields 1433.77% · GIS yields 6.53%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PRTK wins by $465580976.85M in total portfolio value
10 years
PRTK
PRTK
● Live price
1433.77%
Share price
$2.23
Annual div
$31.97
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$465580976.93M
Annual income
$409,409,349,290,672.40
Full PRTK calculator →
GIS
GIS
● Live price
6.53%
Share price
$37.22
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.8K
Annual income
$16,211.26
Full GIS calculator →

Portfolio growth — PRTK vs GIS

📍 PRTK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPRTKGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PRTK + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PRTK pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PRTK
Annual income on $10K today (after 15% tax)
$121,870.18/yr
After 10yr DRIP, annual income (after tax)
$347,997,946,897,071.50/yr
GIS
Annual income on $10K today (after 15% tax)
$554.94/yr
After 10yr DRIP, annual income (after tax)
$13,779.57/yr
At 15% tax rate, PRTK beats the other by $347,997,946,883,291.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PRTK + GIS for your $10,000?

PRTK: 50%GIS: 50%
100% GIS50/50100% PRTK
Portfolio after 10yr
$232790488.50M
Annual income
$204,704,674,653,441.80/yr
Blended yield
87.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PRTK right now

PRTK
Analyst Ratings
5
Buy
2
Hold
Consensus: Buy
Altman Z
-9.7
Piotroski
4/9
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.4% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PRTK buys
0
GIS buys
0
No recent congressional trades found for PRTK or GIS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPRTKGIS
Forward yield1433.77%6.53%
Annual dividend / share$31.97$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.8%
Portfolio after 10y$465580976.93M$78.8K
Annual income after 10y$409,409,349,290,672.40$16,211.26
Total dividends collected$461472805.42M$50.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: PRTK vs GIS ($10,000, DRIP)

YearPRTK PortfolioPRTK Income/yrGIS PortfolioGIS Income/yrGap
1← crossover$154,077$143,376.68$11,502$801.73+$142.6KPRTK
2$2,229,442$2,064,579.75$13,365$1,058.29+$2.22MPRTK
3$30,304,969$27,919,466.07$15,712$1,411.34+$30.29MPRTK
4$387,109,855$354,683,538.63$18,716$1,904.17+$387.09MPRTK
5$4,648,468,715$4,234,261,169.66$22,629$2,603.16+$4648.45MPRTK
6$52,493,108,361$47,519,246,835.85$27,826$3,612.21+$52493.08MPRTK
7$557,675,953,215$501,508,327,268.83$34,871$5,097.54+$557675.92MPRTK
8$5,576,078,691,653$4,979,365,421,713.55$44,643$7,331.52+$5576078.65MPRTK
9$52,496,848,258,695$46,530,444,058,626.19$58,541$10,772.15+$52496848.20MPRTK
10$465,580,976,927,476$409,409,349,290,672.40$78,850$16,211.26+$465580976.85MPRTK

PRTK vs GIS: Complete Analysis 2026

PRTKStock

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Full PRTK Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this PRTK vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PRTK vs SCHDPRTK vs JEPIPRTK vs OPRTK vs KOPRTK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.